每经记者:林姿辰每经编辑:文多丨 2024年11月28日 星期四 丨NO.1 科伦博泰生物拿下首个国产TROP2 ADC药物11月27日,科伦博泰生物发布公告,公司首款用于既往至少接受过2种系统治疗(其中至少1种治疗针对晚期或转移性阶段)的不可切除的局部晚期或转移性三阴性乳腺癌(TNBC)成人患者的国产靶向人滋养细胞表面抗原2(TROP2)的抗体药物偶联物(ADC)芦康沙妥珠单抗(sac-TMT,...
Source Link每经记者:林姿辰每经编辑:文多丨 2024年11月28日 星期四 丨NO.1 科伦博泰生物拿下首个国产TROP2 ADC药物11月27日,科伦博泰生物发布公告,公司首款用于既往至少接受过2种系统治疗(其中至少1种治疗针对晚期或转移性阶段)的不可切除的局部晚期或转移性三阴性乳腺癌(TNBC)成人患者的国产靶向人滋养细胞表面抗原2(TROP2)的抗体药物偶联物(ADC)芦康沙妥珠单抗(sac-TMT,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.